 Teri Schreiner
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 31 | 2023 | 376 | 4.540 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 115 | 1.250 |
Why?
| | Myelitis | 4 | 2020 | 88 | 0.950 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.790 |
Why?
| | Immunosuppressive Agents | 5 | 2023 | 646 | 0.740 |
Why?
| | Cerebral Veins | 1 | 2021 | 15 | 0.740 |
Why?
| | Microvessels | 1 | 2021 | 68 | 0.710 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 61 | 0.700 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 96 | 0.700 |
Why?
| | Nervous System Diseases | 4 | 2019 | 256 | 0.670 |
Why?
| | Venous Thrombosis | 1 | 2021 | 140 | 0.650 |
Why?
| | Sarcoidosis | 1 | 2021 | 135 | 0.640 |
Why?
| | Enterovirus Infections | 5 | 2020 | 160 | 0.600 |
Why?
| | Movement Disorders | 1 | 2017 | 48 | 0.550 |
Why?
| | Muscular Diseases | 1 | 2017 | 104 | 0.540 |
Why?
| | Dimethyl Fumarate | 1 | 2016 | 10 | 0.520 |
Why?
| | HLA-DRB1 Chains | 5 | 2023 | 98 | 0.430 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 183 | 0.420 |
Why?
| | Child | 32 | 2023 | 18420 | 0.410 |
Why?
| | Demyelinating Diseases | 3 | 2023 | 75 | 0.410 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2019 | 69 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 6 | 2023 | 2086 | 0.400 |
Why?
| | Adolescent | 28 | 2023 | 17853 | 0.390 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 72 | 0.370 |
Why?
| | Paralysis | 3 | 2016 | 66 | 0.360 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2020 | 63 | 0.310 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 3 | 2023 | 44 | 0.310 |
Why?
| | Vaccines | 1 | 2014 | 375 | 0.310 |
Why?
| | Neuromuscular Diseases | 2 | 2020 | 89 | 0.310 |
Why?
| | Aquaporin 4 | 3 | 2023 | 87 | 0.300 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 31 | 0.300 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1473 | 0.300 |
Why?
| | Humans | 52 | 2023 | 114705 | 0.300 |
Why?
| | Male | 36 | 2023 | 55607 | 0.290 |
Why?
| | Autoantibodies | 4 | 2023 | 1346 | 0.280 |
Why?
| | Cognition Disorders | 2 | 2022 | 476 | 0.280 |
Why?
| | Case-Control Studies | 11 | 2023 | 3003 | 0.280 |
Why?
| | Cognitive Dysfunction | 2 | 2022 | 284 | 0.270 |
Why?
| | Adjuvants, Immunologic | 2 | 2020 | 206 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 7 | 2023 | 3053 | 0.260 |
Why?
| | Immunologic Factors | 2 | 2019 | 220 | 0.260 |
Why?
| | Vaccination | 1 | 2014 | 1204 | 0.250 |
Why?
| | Treatment Outcome | 4 | 2020 | 9088 | 0.240 |
Why?
| | Vitamin D | 2 | 2019 | 341 | 0.240 |
Why?
| | Rituximab | 3 | 2022 | 150 | 0.240 |
Why?
| | Female | 33 | 2023 | 59521 | 0.240 |
Why?
| | Environmental Exposure | 2 | 2018 | 372 | 0.230 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 72 | 0.230 |
Why?
| | Age of Onset | 6 | 2023 | 446 | 0.220 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 21 | 0.210 |
Why?
| | Immunoglobulin G | 3 | 2022 | 770 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 935 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4411 | 0.190 |
Why?
| | Risk Factors | 11 | 2023 | 8632 | 0.180 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 25 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 81 | 0.170 |
Why?
| | Enterovirus | 1 | 2019 | 72 | 0.160 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 20 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 1880 | 0.160 |
Why?
| | Education, Special | 1 | 2018 | 20 | 0.160 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.160 |
Why?
| | Disabled Persons | 1 | 2020 | 134 | 0.150 |
Why?
| | Fluoxetine | 1 | 2018 | 46 | 0.150 |
Why?
| | Disability Evaluation | 2 | 2020 | 271 | 0.150 |
Why?
| | Electromyography | 2 | 2017 | 326 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 382 | 0.150 |
Why?
| | Child, Preschool | 8 | 2020 | 9118 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2017 | 316 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2023 | 766 | 0.150 |
Why?
| | Neural Conduction | 1 | 2017 | 78 | 0.140 |
Why?
| | Atrophy | 1 | 2017 | 152 | 0.140 |
Why?
| | Recovery of Function | 1 | 2020 | 574 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2018 | 129 | 0.130 |
Why?
| | Attitude | 1 | 2017 | 229 | 0.130 |
Why?
| | Developmental Disabilities | 1 | 2018 | 237 | 0.130 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 30 | 0.130 |
Why?
| | Transgender Persons | 2 | 2016 | 135 | 0.130 |
Why?
| | Dietary Fats | 1 | 2017 | 287 | 0.130 |
Why?
| | Colorado | 4 | 2019 | 4100 | 0.120 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 13 | 0.120 |
Why?
| | Marijuana Abuse | 1 | 2017 | 212 | 0.120 |
Why?
| | Perception | 1 | 2017 | 311 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 250 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2023 | 12556 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 591 | 0.120 |
Why?
| | Gonadal Steroid Hormones | 1 | 2016 | 124 | 0.120 |
Why?
| | Adult | 12 | 2023 | 30553 | 0.120 |
Why?
| | Paraplegia | 1 | 2014 | 52 | 0.120 |
Why?
| | Bone Remodeling | 1 | 2015 | 65 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2017 | 224 | 0.120 |
Why?
| | Motor Neurons | 1 | 2016 | 213 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 728 | 0.110 |
Why?
| | Hypersensitivity | 1 | 2017 | 252 | 0.110 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 61 | 0.110 |
Why?
| | United States | 9 | 2021 | 12186 | 0.110 |
Why?
| | CD40 Antigens | 1 | 2014 | 82 | 0.110 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 127 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2018 | 645 | 0.110 |
Why?
| | MicroRNAs | 1 | 2019 | 600 | 0.110 |
Why?
| | Viral Vaccines | 1 | 2014 | 88 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2540 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 249 | 0.100 |
Why?
| | Medication Adherence | 1 | 2017 | 536 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 383 | 0.100 |
Why?
| | Testosterone | 1 | 2015 | 343 | 0.090 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 125 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 432 | 0.090 |
Why?
| | Disease Progression | 3 | 2023 | 2380 | 0.090 |
Why?
| | Body Composition | 1 | 2015 | 590 | 0.090 |
Why?
| | Transcription Factors | 1 | 2019 | 1528 | 0.090 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 122 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2016 | 574 | 0.090 |
Why?
| | Prospective Studies | 5 | 2020 | 6220 | 0.090 |
Why?
| | Diet | 1 | 2017 | 1080 | 0.090 |
Why?
| | Ultraviolet Rays | 2 | 2023 | 363 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 10471 | 0.080 |
Why?
| | Disease Outbreaks | 3 | 2019 | 307 | 0.080 |
Why?
| | Death, Sudden | 1 | 2009 | 27 | 0.080 |
Why?
| | Body Mass Index | 1 | 2017 | 1959 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 139 | 0.080 |
Why?
| | Vena Cava, Inferior | 1 | 2009 | 56 | 0.080 |
Why?
| | Constriction, Pathologic | 1 | 2009 | 208 | 0.080 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 62 | 0.080 |
Why?
| | Alleles | 2 | 2023 | 789 | 0.080 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 96 | 0.080 |
Why?
| | Genotype | 2 | 2023 | 1760 | 0.070 |
Why?
| | Sweden | 2 | 2017 | 65 | 0.070 |
Why?
| | Neuropsychological Tests | 2 | 2022 | 927 | 0.070 |
Why?
| | Risk | 2 | 2019 | 812 | 0.060 |
Why?
| | Influenza, Human | 1 | 2010 | 546 | 0.060 |
Why?
| | Cohort Studies | 3 | 2020 | 4895 | 0.060 |
Why?
| | Haplotypes | 2 | 2019 | 448 | 0.060 |
Why?
| | Cognition | 2 | 2022 | 989 | 0.060 |
Why?
| | Infant | 4 | 2020 | 7964 | 0.060 |
Why?
| | Middle Aged | 6 | 2020 | 26738 | 0.050 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 29 | 0.050 |
Why?
| | Memory and Learning Tests | 1 | 2022 | 1 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 1841 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1177 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 49 | 0.050 |
Why?
| | Biomarkers | 3 | 2019 | 3408 | 0.050 |
Why?
| | Pandemics | 1 | 2010 | 1320 | 0.050 |
Why?
| | Demography | 1 | 2023 | 260 | 0.050 |
Why?
| | Hospitalization | 1 | 2010 | 1752 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 371 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 122 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 213 | 0.050 |
Why?
| | HLA Antigens | 1 | 2023 | 225 | 0.050 |
Why?
| | Sunlight | 1 | 2021 | 57 | 0.050 |
Why?
| | HIV Infections | 1 | 2015 | 2469 | 0.050 |
Why?
| | Prevalence | 2 | 2017 | 2251 | 0.050 |
Why?
| | Antigens, CD20 | 1 | 2020 | 27 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4410 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 4624 | 0.040 |
Why?
| | Aged | 4 | 2019 | 19074 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 750 | 0.040 |
Why?
| | HLA-A3 Antigen | 1 | 2019 | 6 | 0.040 |
Why?
| | HLA-B7 Antigen | 1 | 2019 | 7 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 676 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| | Propensity Score | 1 | 2020 | 224 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 24 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 160 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 663 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 287 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 333 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 235 | 0.040 |
Why?
| | California | 1 | 2019 | 353 | 0.040 |
Why?
| | Habits | 1 | 2017 | 36 | 0.040 |
Why?
| | Geography, Medical | 1 | 2017 | 10 | 0.040 |
Why?
| | Knowledge | 1 | 2017 | 49 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 228 | 0.040 |
Why?
| | Water Quality | 1 | 2017 | 28 | 0.040 |
Why?
| | Family | 1 | 2021 | 589 | 0.040 |
Why?
| | Reading | 1 | 2018 | 149 | 0.040 |
Why?
| | Diet Surveys | 1 | 2017 | 78 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 43 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 133 | 0.030 |
Why?
| | North America | 1 | 2017 | 256 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1168 | 0.030 |
Why?
| | Brain | 2 | 2019 | 2371 | 0.030 |
Why?
| | Gender Identity | 1 | 2016 | 102 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 169 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 945 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 381 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 345 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1660 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1430 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 101 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2387 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 355 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 455 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 696 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 219 | 0.030 |
Why?
| | Cell Separation | 1 | 2014 | 291 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1518 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2017 | 635 | 0.030 |
Why?
| | Animals | 1 | 2014 | 31709 | 0.030 |
Why?
| | Muscle Strength | 1 | 2015 | 271 | 0.020 |
Why?
| | Acute Disease | 1 | 2014 | 911 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1083 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6116 | 0.020 |
Why?
| | Autopsy | 1 | 2009 | 84 | 0.020 |
Why?
| | Parents | 1 | 2017 | 1186 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 813 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 523 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 230 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4516 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2797 | 0.020 |
Why?
| | Asthma | 1 | 2017 | 2029 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 2894 | 0.010 |
Why?
|
|
Schreiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|